Overview

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA)

Status:
RECRUITING
Trial end date:
2027-10-31
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-related macular degeneration (AMD).
Phase:
PHASE3
Details
Lead Sponsor:
Annexon, Inc.